DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback